DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 214 filers reported holding DENALI THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $475 | +28.0% | 16,097 | 0.0% | 0.02% | +16.7% |
| Q1 2023 | $371 | -54.6% | 16,097 | -45.3% | 0.02% | -60.0% |
| Q4 2022 | $818 | -99.7% | 29,426 | +285.5% | 0.04% | +221.4% |
| Q3 2022 | $234,000 | -52.1% | 7,634 | -49.8% | 0.01% | -56.2% |
| Q1 2022 | $489,000 | +48.6% | 15,203 | +106.3% | 0.03% | -22.0% |
| Q4 2021 | $329,000 | -11.6% | 7,369 | 0.0% | 0.04% | -18.0% |
| Q3 2021 | $372,000 | -31.1% | 7,369 | -76.2% | 0.05% | -68.9% |
| Q4 2019 | $540,000 | – | 30,974 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |